Company intelligence / Profile preview

Biota Scientific Management

Notting Hill, Victoria, Australia

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Biota Scientific Management’s most advanced asset is laninamivir octanoate hydrate (neuraminidase inhibitor, marketed as Inavir in Japan), approved for influenza A/B treatment. They also developed zanamivir (marketed as Relenza by GSK) and have internal and partnered programs for HRV, RSV, Hepatitis C, and novel antibacterials. Vapendavir for chronic respiratory diseases reached Phase 2. Many programs are discontinued or pending further development[1][4][7].

Therapeutic areas: PulmonologyDermatologyInfectious Diseases
Modalities: Small moleculeBiologicNeuraminidase inhibitorsHRV capsid inhibitorsProtein inhibitors
Industry: Biotech

Partnerships

Daiichi Sankyo (laninamivir)GlaxoSmithKline (zanamivir/Relenza)Boehringer Ingelheim (former HCV collaboration)

Beyond the preview

Go deeper on Biota Scientific Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biota Scientific Management.

Explore the full profile